



Department
of Health

Medicaid NYRx

NYRx Education & Outreach MCO Newsletter

[Highlights](#) | [Publications](#) | [Quicklinks](#) | [About](#) | [Weekly Webinars](#) | [Contact](#)

June 2026

Highlights

Urgent Medical Device Correction – Omnipod® from Insulet: UPDATE

On May 26, 2026, Insulet initiated a Voluntary Medical Device Correction for certain Omnipod products in the U.S. and affected international markets. [Certain Pods from specific lots](#) may have a small tear in the tubing just above the skin. If this occurs, insulin may leak outside of the Pod instead of being fully infused in the body as intended, potentially leading to under-delivery of insulin.

Affected products include:

- Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods
- Lot Numbers: Click [here](#) to check if your Pod(s) is affected.

Pods not included in these lots, as well as other Omnipod® products, remain safe to use.

Managed Care Organizations (MCOs) should be aware of the issue and be prepared to advise Medicaid members and providers on how to identify affected products and obtain replacements.

For further information, refer to the [NYRx Notice to Providers, Pharmacies, and MCOs: Urgent Medical Device Correction – Omnipod® from Insulet: UPDATE](#).



Top ↑

Criteria Requirements for Ozempic 1.5 mg and Rybelsus 3 mg Tablets

NYRx, the Medicaid Pharmacy Program, covers medically necessary FDA-approved or compendia-supported drugs when used for a Medicaid-covered indication. MCOs should be aware of updated clinical criteria and coverage limitations for Ozempic 1.5 mg and Rybelsus 3mg tablets.



Both Ozempic 1.5 mg and Rybelsus 3 mg tablets are subject to the following clinical criteria:

- Prescriptions will be limited to a duration of 30 days, with no refills.
- Use for glycemic control will not be covered.

Pharmacy providers should be aware of this clinical criteria, monitor for rejected claims, and coordinate with prescribers to update prescriptions as necessary. Prescribers should consider preferred products listed in the [NYRx Preferred Drug Quick List](#). Preferred products should be prescribed whenever clinically appropriate.

For further information, refer to the [NYRx Clinical Criteria Update](#) for Ozempic and Rybelsus Tablets.



[Top ↑](#)

NYS Medicaid Prior Authorization Updates for Enteral Nutrition Formula

A reminder: In addition to regulatory changes, New York State Medicaid updated its prior authorization requirements for enteral nutrition formula.

- **Oral-fed members:** Calorie limits approved through the Enteral Web Portal and Interactive Voice Response (IVR) prior authorization systems will be increased from 1,000 calories per day to 1,250 calories per day.
- **Tube-fed members:** Calorie limits approved through the Enteral Web Portal and Interactive Voice Response (IVR) prior authorization systems will be increased from 2,000 calories per day to 2,500 calories per day.



Department
of Health

Medicaid NYRx

Questions related to this update should be directed to the Bureau of Medical Review at 1-800-342-3005 or OHIPMEDPA@health.ny.gov.

For more information, see the [Enteral Nutrition Regulatory Amendment publication](#).



[Top ↑](#)

Publications

Click to access [NYRx, the Medicaid Pharmacy Program](#) website for these publications and more:

- Billing & Coordination of Benefits
- Drug Class Coverage Overviews
- Newsletters
- Notifications
- Prior Authorization Information

[Top ↑](#)

Quicklinks



[NYRx Preferred Drug List](#)



[NYRx Preferred Drug Quick List](#)



[NYRx eMedNY Formulary File](#)



[NYRx Brand Less Than Generic Program Updates](#)



[NYRx Preferred Diabetic Supply Program](#)

[Top ↑](#)

About the NYRx E&O Team

The NYRx E&O team serves as a liaison between all stakeholders and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:



- Managed Care Plans
- Case workers and NYS agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care Children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C

[Top ↑](#)

Weekly Webinars

To register, please visit the [NYRx Education & Outreach](#) website.

Prescriber Webinar

Mondays

12 PM – 1 PM ET

Pharmacy Webinar

Wednesdays

12 PM – 1 PM ET

NYRx, the Medicaid Pharmacy Program

Fridays

12 PM – 1 PM ET

[Top ↑](#)

Contact Us

Office Hour Q&A Pop-In

Mondays and Wednesdays

12 PM – 1 PM ET

[Click here to join.](#)



Meet with the Team

The NYRx E&O team meets with various stakeholders throughout the month. Would you like to request a meeting with us? [Click here.](#)

NYRx E&O Call Center

1-833-967-7310

Monday – Friday

8 AM – 5 PM ET

Excludes Holidays



[Top ↑](#)



[Website](#)



[Email](#)



[NYRx E&O Channel](#)



[NYS Public Health Now Podcast](#)